TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma

Plasma circulating tumor DNA (ctDNA) with tumor-specific mutations is an attractive biomarker. The telomerase reverse transcriptase (TERT) C228T promoter mutation is the most prevalent tumor-associated mutation in hepatocellular carcinoma (HCC). We evaluated the presence and prognostic value of the TERT C228T mutation in plasma and tissue in a Danish HCC cohort.We analyzed ctDNA from 95 HCC patients and 45 liver cirrhotic patients without HCC...